UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’

Nature (London), 2011-04, Vol.472 (7344), p.471-475

2011

Volltextzugriff (PDF)

Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice

Nature communications, 2023-10, Vol.14 (1), p.6330-6330, Article 6330

2023

Volltextzugriff (PDF)

Inhibitory affinity modulation of FcγRIIA ligand binding by glycosphingolipids by inside-out signaling

Cell reports (Cambridge), 2021-05, Vol.35 (7), p.109142-109142, Article 109142

2021

Volltextzugriff (PDF)

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

PloS one, 2016-11, Vol.11 (11), p.e0165909-e0165909

2016

Volltextzugriff (PDF)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Frontiers in oncology, 2022-05, Vol.12, p.869078-869078

2022

Volltextzugriff (PDF)

Abstract OT1-18-05: A multicenter, open-label, phase 2 study of Imprime PGG and pembrolizumab in patients with metastatic breast cancer who have progressed through prior hormonal therapy

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-18-05-OT1-18-05

2022

Volltextzugriff (PDF)

A multicenter, open-label, phase 2 study of odetiglucan (IMPRIME PGG) and pembrolizumab in patients with metastatic breast cancer (mBCA) who have progressed through prior hormonal therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1115-TPS1115

2022

Volltextzugriff (PDF)

A multicenter, open-label, phase 1a/b study of HC-7366, a modulator of integrated stress response (ISR) kinase GCN2 in subjects with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3179-TPS3179

2022

Volltextzugriff (PDF)

5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S13-S13

2024

Volltextzugriff (PDF)

Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML

Blood, 2023-11, Vol.142 (Supplement 1), p.2943-2943

2023

Volltextzugriff (PDF)

Abstract 3247: Combination therapy using PERK and PD1/PD-L1 inhibitors reprograms tumor associated macrophages and reduces tumor burden

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3247-3247

2023

Volltextzugriff (PDF)

Secretory products of breast cancer cells upregulate hyaluronan production in a human osteoblast cell line

Clinical & experimental metastasis, 2005-12, Vol.22 (8), p.629-642

2005

Volltextzugriff (PDF)

A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4201-TPS4201

2023

Volltextzugriff (PDF)

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

Clinical cancer research, 2023-12, Vol.29 (23), p.4870-4882

2023

Volltextzugriff (PDF)

AAI Curriculum Ad Hoc Committee Presentation: The Development of AAI Recommendations for an Undergraduate Course in Immunology

The Journal of immunology (1950), 2021-05, Vol.206 (1_Supplement), p.54-54.09

2021

Volltextzugriff (PDF)

Abstract 4708: Imprime (beta-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4708-4708

2018

Volltextzugriff (PDF)

Rapid Cloning For Protein Crystallography Using Type IIS Restriction Enzymes

Crystal growth & design, 2013-07, Vol.13 (7), p.2833-2839

2013

Volltextzugriff (PDF)

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Anticancer research, 2020-03, Vol.40 (3), p.1467-1473

2020

Volltextzugriff (PDF)

Abstract 4666: HC-7366, a potent GCN2 kinase activator, augments osimertinib therapy to delay resistance in EGFR mutant NSCLC models

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.4666-4666

2024

Volltextzugriff (PDF)

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Volltextzugriff (PDF)

Abstract 3280: Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3280-3280

2016

Volltextzugriff (PDF)

Abstract PD1-02: Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD1-02-PD1-02

2020

Volltextzugriff (PDF)

Abstract PR-10: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy

Cancer research (Chicago, Ill.), 2024-09, Vol.84 (17_Supplement_2), p.PR-10-PR-10

2024

Volltextzugriff (PDF)

Abstract B061: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy

Cancer research (Chicago, Ill.), 2024-09, Vol.84 (17_Supplement_2), p.B061-B061

2024

Volltextzugriff (PDF)

Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.LB-129-LB-129

2018

Volltextzugriff (PDF)

1 – 25 von 110

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Englisch
(110)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’

Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice

Inhibitory affinity modulation of FcγRIIA ligand binding by glycosphingolipids by inside-out signaling

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Abstract OT1-18-05: A multicenter, open-label, phase 2 study of Imprime PGG and pembrolizumab in patients with metastatic breast cancer who have progressed through prior hormonal therapy

A multicenter, open-label, phase 2 study of odetiglucan (IMPRIME PGG) and pembrolizumab in patients with metastatic breast cancer (mBCA) who have progressed through prior hormonal therapy

A multicenter, open-label, phase 1a/b study of HC-7366, a modulator of integrated stress response (ISR) kinase GCN2 in subjects with advanced solid tumors

5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605

Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML

Abstract 3247: Combination therapy using PERK and PD1/PD-L1 inhibitors reprograms tumor associated macrophages and reduces tumor burden

Secretory products of breast cancer cells upregulate hyaluronan production in a human osteoblast cell line

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

AAI Curriculum Ad Hoc Committee Presentation: The Development of AAI Recommendations for an Undergraduate Course in Immunology

Abstract 4708: Imprime (beta-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

Rapid Cloning For Protein Crystallography Using Type IIS Restriction Enzymes

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Abstract 4666: HC-7366, a potent GCN2 kinase activator, augments osimertinib therapy to delay resistance in EGFR mutant NSCLC models

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Abstract 3280: Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo

Abstract PD1-02: Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Abstract PR-10: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy

Abstract B061: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy

Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients

Suchergebnisse filtern